All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
During the 41st Annual Dermatology Conference held in Kuching, Sarawak, Professor Steven R. Feldman updated the participants on the latest in topical treatment of psoriasis. Highlights from the presentation are summarized below.
At the 7th Galderma Skin Day, leading dermatologists, Dr Najeeb Ahmad Mohd Safdar of Hospital Tuanku Ja’afar, Seremban and Dr Derrick Aw of the National University Hospital, Singapore, presented on managing atopic dermatitis and hand eczema, with a special focus on Cetaphil® Restoraderm (Galderma) and the newly launched Nutraplus® (Galderma).
At the 7th Galderma Skin Day, renowned dermatologists, Dr Derrick Aw of the National University Hospital, Singapore and Dr Chan Lee Chin of Penang Hospital, shared practice pearls on managing melasma and acne.
Dr. Ch’ng Chin Chwen, Prof. Maria Teresita Gabriel, 20161017023629
A 42-year-old Pakistani female consulted for spontaneously occurring generalized wheals of 6 months duration. She noticed that the wheals mostly appeared on her upper body and were erythematous, painful, pruritic, and unsightly.
Prof. Maria Teresita Gabriel, Prof. Kanokvalai Kulthanan, 20160805061403
A 66-year-old Filipino female dressmaker sought consult due to pruritus with the appearance of about less than 20 wheals on both of her forearms and wrists. This condition appeared 2 weeks prior to consult. There was no rapid swelling or angioedema noted and symptoms did not have a pattern.
Although topical corticosteroids are effective for the treatment of seborrheic dermatitis, long-term use of these agents is limited by side effects. Moreover, increased understanding of the possible contribution of yeast species to the pathogenesis of the disease suggests that corticosteroids may also be limited by their lack of antifungal efficacy. By contrast, novel nonsteroidal treatments offer great promise. At the 2nd Asia Pacific Meeting of Experts in Dermatology (APMED) held recently in Hanoi, Vietnam, Associate Professor Neal Bhatia, from the Harbor-UCLA Medical Center, Los Angeles, California, US, discussed the potential benefits of new agents such as SebclairTM (Menarini), which combines anti-inflammatory and antifungal properties to effectively treat the symptoms of seborrheic dermatitis.
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
At the Dermatological Society of Malaysia Midterm Meeting 2016, Professor Goh Chee Leok shared practical tips in diagnosing hand eczema and its current management strategies, with a special focus on the role of primary and secondary prevention in hand eczema management.
A recent study shows cefalexin is effective for treating uncomplicated cellulitis caused by streptococcal species and methicillin-susceptible Staphylococcus aureus (MSSA). [Mayo Clin Proc2014;89(10):1436–1451]
New drug applications approved by US FDA as of 1 - 15 Feb 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.